- SEK40.25bn
- SEK37.71bn
- SEK1.72bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 44.9 | ||
| PEG Ratio (f) | 0.79 | ||
| EPS Growth (f) | 133.58% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 13.75 | ||
| Price to Tang. Book | 13.85 | ||
| Price to Free Cashflow | 62.56 | ||
| Price to Sales | 25.26 | ||
| EV to EBITDA | 145.54 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 7.88% | ||
| Return on Equity | 10.36% | ||
| Operating Margin | 14.86% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | SEKm | 105.61 | 336 | 600.57 | 956.34 | 1,716.85 | 1,932.31 | 3,175.69 | 103.39% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | +753.94 | -18.14 | +210.45 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Camurus AB is a Sweden-based research and development based pharmaceutical and biotechnology company with a focus on the development and marketing of specialty medicines, providing patients suffering from severe and chronic disease, such as opioid dependence, pain, cancer, and endocrine diseases. The Company has a diversified research portfolio, which includes products in clinical trials. The Company’s products are based on FluidCrystal formulation technology. FluidCrystal is Company's patent-protected technology platform. Camurus AB is the parent company of the Group, which comprises of legal entities, namely: Camurus Inc, Cubosome Inc, Development AB, Camurus GmbH, Camurus Ltd, Camurus Oy, Camurus AS, Camurus SAS, Camurus Pty Ltd, Camurus S.L, Camurus ApS, Camurus BV and Camurus Austria GmbH.
Directors
- Per Wallstrom CHM (71)
- Fredrik Tiberg PRE (57)
- Eva Pinotti-Lindqvist CFO (58)
- Torsten Malmstrom CTO (52)
- Annette Mattsson VPR (54)
- Agneta Svedberg VPR (57)
- Fredrik Joabsson VBD (48)
- Andrew McLean VBD
- Peter Hjelmstrom OTH (48)
- Richard Jameson OTH (56)
- Hege Hellstrom IND (56)
- Martin Jonsson IND (59)
- Mark Never IND (59)
- Behshad Sheldon IND (57)
- Ole Vahlgren IND (58)
- Kerstin Valinder Strinnholm IND (61)
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- October 8th, 2004
- Public Since
- December 3rd, 2015
- No. of Shareholders
- 11,974
- No. of Employees
- 228
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
OMX Nordic Exchange Stockholm- Shares in Issue
- 58,636,918
- Address
- Ideongatan 1A, LUND, 223 62
- Web
- https://www.camurus.com/
- Phone
- +46 462865730
- Contact
- Fredrik Joabsson
- Auditors
- PricewaterhouseCoopers AB
Upcoming Events for CAMX
Q3 2024 Camurus AB Earnings Release
Camurus AB at Jefferies London Healthcare Conference
Q4 2024 Camurus AB Earnings Release
Similar to CAMX
Biogaia AB
OMX Nordic Exchange Stockholm
BoneSupport Holding AB
OMX Nordic Exchange Stockholm
Calliditas Therapeutics AB
OMX Nordic Exchange Stockholm
Cinclus Pharma Holding publ AB
OMX Nordic Exchange Stockholm
Corline Biomedical AB
OMX Nordic Exchange Stockholm
FAQ
What is the Camurus AB share price?
As of Today at 20:14 UTC, shares in Camurus AB are trading at SEK686.50. This share price information is delayed by 15 minutes.
How has the Camurus AB share price performed this year?
Shares in Camurus AB last closed at SEK686.50 and the price had moved by +136.07% over the past 365 days. In terms of relative price strength the Camurus AB share price has outperformed the FTSE Global All Cap Index by +112.92% over the past year.
What are the analyst and broker recommendations for Camurus AB?
The overall consensus recommendation for Camurus AB is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Camurus AB dividend yield?
Camurus AB does not currently pay a dividend.
Does Camurus AB pay a dividend?
Camurus AB does not currently pay a dividend.
When does Camurus AB next pay dividends?
Camurus AB does not currently pay a dividend.
How do I buy Camurus AB shares?
To buy shares in Camurus AB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Camurus AB?
As of the previous close price of SEK686.50, shares in Camurus AB had a market capitalisation of SEK40.25bn.
Where are Camurus AB shares listed?
Here are the trading details for Camurus AB:
- Country of listing: Sweden
- Exchange: STO
- Ticker Symbol: CAMX
What kind of share is Camurus AB?
Based on an overall assessment of its quality, value and momentum Camurus AB is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Camurus AB share price forecast for 2024?
The analyst consensus target price for shares in Camurus AB is SEK705.50. That is 2.77% above the last closing price of SEK686.50.
Analysts covering Camurus AB currently have a consensus Earnings Per Share (EPS) forecast of SEK6.15 for the next financial year.
Find out moreWhat is the trend in the Camurus AB share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Camurus AB. Over the past six months, its share price has outperformed the FTSE Global All Cap Index by +32.53%.
As of the last closing price of SEK686.50, shares in Camurus AB were trading +22.64% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Camurus AB PE Ratio?
The Camurus AB PE ratio based on its reported earnings over the past 12 months is 44.9. The shares last closed at SEK686.50.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Camurus AB?
Camurus AB's management team is headed by:
- Per Wallstrom - CHM
- Fredrik Tiberg - PRE
- Eva Pinotti-Lindqvist - CFO
- Torsten Malmstrom - CTO
- Annette Mattsson - VPR
- Agneta Svedberg - VPR
- Fredrik Joabsson - VBD
- Andrew McLean - VBD
- Peter Hjelmstrom - OTH
- Richard Jameson - OTH
- Hege Hellstrom - IND
- Martin Jonsson - IND
- Mark Never - IND
- Behshad Sheldon - IND
- Ole Vahlgren - IND
- Kerstin Valinder Strinnholm - IND